PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Parecoxib in Renal Colic
Phase 3
Terminated
- Conditions
- Colic
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00139646
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Siena, Italy
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00139711
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Varses, Italy
Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
Phase 4
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 137
- Registration Number
- NCT00140036
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Fleurimont, Quebec, Canada
US Inhaled Insulin Therapeutic Choice Questionnaire Study
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2007-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 740
- Registration Number
- NCT00139763
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Phase 3
Completed
- Conditions
- Adenocarcinoma
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2011-05-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 606
- Registration Number
- NCT00140075
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
Phase 3
Completed
- Conditions
- Community-Acquired Pneumonia
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT00140023
- Locations
- ๐ต๐ญ
Pfizer Investigational Site, Quezon City, Philippines
Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception
Phase 4
Completed
- Conditions
- ContraceptionBone Density
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT00139685
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Norfolk, Virginia, United States
A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00139672
Parecoxib In Post Surgery (Hemicolectomy) Pain
Phase 3
Terminated
- Conditions
- Colectomy
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00139607
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Siena, Italy
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
Phase 3
Completed
- Conditions
- AsthmaDiabetes Mellitus
- Interventions
- Drug: Subcutaneous Insulin
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 288
- Registration Number
- NCT00139659
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Neuss, Germany
ยฉ Copyright 2025. All Rights Reserved by MedPath